• Member Statistics

    • 759,505 Colleagues-to-Date [Sponsored by a generous R&D grant from iMBA, Inc.]
  • David E. Marcinko [Editor-in-Chief]

    As a former Dean and appointed Distinguished University Professor and Endowed Department Chair, Dr. David Edward Marcinko MBA was a NYSE broker and investment banker for a decade who was respected for his unique perspectives, balanced contrarian thinking and measured judgment to influence key decision makers in strategic education, health economics, finance, investing and public policy management.

    Dr. Marcinko is originally from Loyola University MD, Temple University in Philadelphia and the Milton S. Hershey Medical Center in PA; as well as Oglethorpe University and Emory University in Georgia, the Atlanta Hospital & Medical Center; Kellogg-Keller Graduate School of Business and Management in Chicago, and the Aachen City University Hospital, Koln-Germany. He became one of the most innovative global thought leaders in medical business entrepreneurship today by leveraging and adding value with strategies to grow revenues and EBITDA while reducing non-essential expenditures and improving dated operational in-efficiencies.

    Professor David Marcinko was a board certified surgical fellow, hospital medical staff President, public and population health advocate, and Chief Executive & Education Officer with more than 425 published papers; 5,150 op-ed pieces and over 135+ domestic / international presentations to his credit; including the top ten [10] biggest drug, DME and pharmaceutical companies and financial services firms in the nation. He is also a best-selling Amazon author with 30 published academic text books in four languages [National Institute of Health, Library of Congress and Library of Medicine].

    Dr. David E. Marcinko is past Editor-in-Chief of the prestigious “Journal of Health Care Finance”, and a former Certified Financial Planner® who was named “Health Economist of the Year” in 2010. He is a Federal and State court approved expert witness featured in hundreds of peer reviewed medical, business, economics trade journals and publications [AMA, ADA, APMA, AAOS, Physicians Practice, Investment Advisor, Physician’s Money Digest and MD News] etc.

    Later, Dr. Marcinko was a vital recruited BOD member of several innovative companies like Physicians Nexus, First Global Financial Advisors and the Physician Services Group Inc; as well as mentor and coach for Deloitte-Touche and other start-up firms in Silicon Valley, CA.

    As a state licensed life, P&C and health insurance agent; and dual SEC registered investment advisor and representative, Marcinko was Founding Dean of the fiduciary and niche focused CERTIFIED MEDICAL PLANNER® chartered professional designation education program; as well as Chief Editor of the three print format HEALTH DICTIONARY SERIES® and online Wiki Project.

    Dr. David E. Marcinko’s professional memberships included: ASHE, AHIMA, ACHE, ACME, ACPE, MGMA, FMMA, FPA and HIMSS. He was a MSFT Beta tester, Google Scholar, “H” Index favorite and one of LinkedIn’s “Top Cited Voices”.

    Marcinko is “ex-officio” and R&D Scholar-on-Sabbatical for iMBA, Inc. who was recently appointed to the MedBlob® [military encrypted medical data warehouse and health information exchange] Advisory Board.



  • ME-P Information & Content Channels

  • ME-P Archives Silo [2006 – 2019]

  • Ann Miller RN MHA [Managing Editor]

    USNews.com, Reuters.com,
    News Alloy.com,
    and Congress.org

    Comprehensive Financial Planning Strategies for Doctors and Advisors: Best Practices from Leading Consultants and Certified Medical Planners(TM)

    Product Details

    Product Details

    Product Details


    New "Self-Directed" Study Option SinceJanuary 1st, 2018
  • Most Recent ME-Ps

  • PodiatryPrep.org

    Lower Extremity Trauma
    [Click on Image to Enlarge]

  • ME-P Free Advertising Consultation

    The “Medical Executive-Post” is about connecting doctors, health care executives and modern consulting advisors. It’s about free-enterprise, business, practice, policy, personal financial planning and wealth building capitalism. We have an attitude that’s independent, outspoken, intelligent and so Next-Gen; often edgy, usually controversial. And, our consultants “got fly”, just like U. Read it! Write it! Post it! “Medical Executive-Post”. Call or email us for your FREE advertising and sales consultation TODAY [770.448.0769]

    Product Details

    Product Details

  • Medical & Surgical e-Consent Forms

  • iMBA R&D Services

    Commission a Subject Matter Expert Report [$250-$999]January 1st, 2019
    Medical Clinic Valuations * Endowment Fund Management * Health Capital Formation * Investment Policy Statement Analysis * Provider Contracting & Negotiations * Marketplace Competition * Revenue Cycle Enhancements; and more! HEALTHCARE FINANCIAL INDUSTRIAL COMPLEX
  • iMBA Inc., OFFICES

    Suite #5901 Wilbanks Drive, Norcross, Georgia, 30092 USA [1.770.448.0769]. Our location is real and we are now virtually enabled to assist new long distance clients and out-of-town colleagues.

  • ME-P Publishing


    If you want the opportunity to work with leading health care industry insiders, innovators and watchers, the “ME-P” may be right for you? We are unbiased and operate at the nexus of theoretical and applied R&D. Collaborate with us and you’ll put your brand in front of a smart & tightly focused demographic; one at the forefront of our emerging healthcare free marketplace of informed and professional “movers and shakers.” Our Ad Rate Card is available upon request [770-448-0769].

  • Reader Comments, Quips, Opinions, News & Updates

  • Start-Up Advice for Businesses, DRs and Entrepreneurs

    ImageProxy “Providing Management, Financial and Business Solutions for Modernity”
  • Up-Trending ME-Ps

  • Capitalism and Free Enterprise Advocacy

    Whether you’re a mature CXO, physician or start-up entrepreneur in need of management, financial, HR or business planning information on free markets and competition, the "Medical Executive-Post” is the online place to meet for Capitalism 2.0 collaboration. Support our online development, and advance our onground research initiatives in free market economics, as we seek to showcase the brightest Next-Gen minds. ******************************************************************** THE ME-P DISCLAIMER: Posts, comments and opinions do not necessarily represent iMBA, Inc., but become our property after submission. Copyright © 2006 to-date. iMBA, Inc allows colleges, universities, medical and financial professionals and related clinics, hospitals and non-profit healthcare organizations to distribute our proprietary essays, photos, videos, audios and other documents; etc. However, please review copyright and usage information for each individual asset before submission to us, and/or placement on your publication or web site. Attestation references, citations and/or back-links are required. All other assets are property of the individual copyright holder.
  • OIG Fraud Warnings

    Beware of health insurance marketplace scams OIG's Most Wanted Fugitives at oig.hhs.gov

About Theranos

Join Our Mailing List 

What is Is – How it Works

[By Staff Reporters]

The next time your doctor recommends a blood test, you may be able to swing by your local Walgreens. You can have your finger pricked and receive results within four hours. The process of blood testing has remained the same since the 1960s. Doctors and nurses drawing vials of blood, from you, that are sent to labs leaving patients waiting for results for days or weeks.




Enter Theranos

Theranos is a privately held health technology and medical laboratory services company based in Palo Alto, California that provides blood tests. The company’s blood testing platform uses a few drops of blood obtained via a fingerstick rather than vials of blood obtained via traditional venipuncture, using microfluidics technology.

Link: http://en.wikipedia.org/wiki/Theranos

Founder Elizabeth Holmes

At 30, Elizabeth Holmes makes her debut on the Forbes 400 as the youngest self-made woman billionaire. She dropped out her sophomore year of Stanford University to found Palo Alto, Calif.-based blood testing company Theranos in 2003 with money she saved for college. With a painless prick, her labs can quickly test a drop of blood at a fraction of the price of commercial labs which need more than one vial. Theranos has raised $400 million from venture capitalists, valuing the company at $9 billion, and Holmes’ 50% stake at $4.5 billion. She has assembled a stellar board that includes elder statesmen George Shultz and Henry Kissinger. Last year, Walgreens, the largest U.S. retail pharmacy chain, with more than 8,100 stores, announced plans to roll out Theranos Wellness Centers inside its pharmacies.

Link: http://news.therawfoodworld.com/walgreens-implements-new-technology-uses-just-one-drop-blood-run-dozens-tests/


blood test



Your thoughts and comments on this ME-P are appreciated. Feel free to review our top-left column, and top-right sidebar materials, links, URLs and related websites, too. Then, subscribe to the ME-P. It is fast, free and secure.

Speaker: If you need a moderator or speaker for an upcoming event, Dr. David E. Marcinko; MBA – Publisher-in-Chief of the Medical Executive-Post – is available for seminar or speaking engagements. Contact: MarcinkoAdvisors@msn.com


Product DetailsProduct Details

15 Responses

  1. America’s Youngest Female Billionaire

    Elizabeth Holmes – Explains Why She’s Transforming Medicine thru Theranos.




  2. A $10,169 blood test is everything wrong with American health care

    This huge variation in the price of a really simple, incredibly basic blood test tells us a few things about the American health care system.




  3. Blood Panels

    Consumers will soon be able to bypass their doctors by going online to order cholesterol readings, thyroid tests and other bloodwork from the biggest diagnostics company in the U.S.


    Laboratory Corp. of America Holdings will let customers go online to pay for tests, visit a service center to get blood drawn, then view the results on the Web. The company has already been doing back-office lab work for a number of Internet firms that let people order up tests without a doctor.



  4. Startup to Cut Breast Cancer Testing Costs

    A Burlingame, Calif.-based startup called Color Genomics is announcing that it will provided genetic testing for breast and ovarian cancer – the same genetic tests that led Angelina Jolie to have her breasts and ovaries surgically removed – at one-sixteenth the cost of the main test that is currently used.




  5. Theranos strikes deal with Capital BlueCross, lands on East Coast

    The testing company that could upend America’s diagnostics market will partner with Capital BlueCross in Harrisburg, Pennsylvania, to bring the company’s new direct-to-consumer blood testing options to the insurer’s 1.3 million members.




  6. The Backstory – FROM the HopeLab WEBSITE

    In the late 1980s, HopeLab founder Pam Omidyar spent her days as a research assistant in an immunology lab. At night, after hours watching malignant cancer cells multiply under a microscope, she unwound by playing video games with her husband, Pierre Omidyar, the software engineer who went on to found eBay. As a scientist and game enthusiast, Pam began to wonder if giving young cancer patients a chance to blast their cancer in a video game might actually improve their health. In 2001, Pam founded HopeLab to develop and test this concept, which led to our first product, Re-Mission.

    The Big Idea

    Today we’re working to harness the power and appeal of technology to improve human health and well-being. Re-Mission demonstrated that specially designed technology can be both fun and effective in driving positive health behavior. Zamzee, another product developed at HopeLab, deepened our understanding of how to motivate and sustain healthy behavior change. Our work now focuses on the research and development of new social technologies to promote human resilience and improve both psychological and biological health and well-being.

    Visit the Join Us page to learn more about HopeLab’s values and culture http://www.hopelab.org/about-us/

    HopeLab is part of The Omidyar Group. For more information about the Omidyars’ personal, professional and philanthropic interests, visit http://www.OmidyarGroup.com

    via Ann Miller RN MHA


  7. The Wall Street Journal Attacks

    Healthcare startup Theranos just deepened its war with the Wall Street Journal, charging that the paper’s recent exposé into its blood testing practices is “simply wrong.”



    Dr. David E. Marcinko MBA


  8. Time Running out for THERANOS?

    When Theranos CEO Elizabeth Holmes sat down for an interview last month, she sought to address reports that sparked serious doubts about her company’s innovative blood- testing technology.


    Hope Hetico RN MHA


  9. A Drop of Blood Gives Cancer Patients Peace of Mind
    [The NEW Theranos?]

    A blood test can tell people if they’ve won their battle with cancer or not. A new study shows that liquid biopsies—which use gene-sequencing to scan a blood sample for DNA, rather than analyzing a chunk of excised tissue—can categorize cancer survivors as very likely cured or at a big risk for a relapse.

    MIT Data from 230 people undergoing surgery for colon cancer showed that 79 percent of patients whose blood still contained tumor DNA after surgery eventually relapsed, while only 9.8 percent of those who tested negative did. Some scientists are predicting that these kinds of tests could become a universal screening method, used to catch cancers early, when they’re most curable.

    So it’s perhaps not surprising that investors aren’t far behind the science: a startup called Grail, which is pursuing a doctor’s office screening test able to spot any cancer, raised $100 million earlier this year.



  10. Updates

    The blood testing startup Theranos has been under heavy scrutiny for months, but now regulators have banned its CEO from owning or operating a medical laboratory for at least two years.


    Meanwhile Juno Therapeutics, which has been developing a treatment for leukemia using genetically engineered white blood cells, has had to cut its latest trial short because two patients have died from neurotoxicity-related complications.

    Dr. David Marcinko MBA


  11. Bad Blood

    The beleaguered blood-testing company Theranos has announced that it will close its testing labs and cut 340 staff. In an open letter, the company’s CEO, Elizabeth Holmes, explained that Thernaos has spent months “assessing [its] strengths and addressing … weaknesses.”

    Its weaknesses, if you didn’t know already, are all the clinical labs and Wellness Centers that it operates, which are now to close. Instead, Theranos will turn its attention to a so-called MiniLab—a small, Internet-connected device capable of performing an array of blood tests, which was announced over the summer. That may be the only way Holmes can think of to continue running the company, given she was banned from operating clinical labs by U.S. regulators earlier this year.

    The pivot may be Holmes’ last resort, but it certainly doesn’t promise success. At this stage, the reputation of Theranos is in tatters: once valued at $9 billion, its catastrophic series of errors has seen Forbes value the company at zero.

    MIT Review


  12. FRAUD

    Theranos CEO and former president charged with massive fraud.


    Dr. David Marcinko MBA


  13. Theranos

    More bad news and a book review.


    Dr. David E. Marcinko MBA

    Liked by 1 person

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: